Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Five year distribution agreement

4 Jan 2010 07:00

RNS Number : 9261E
Immunodiagnostic Systems Hldgs PLC
04 January 2010
 



Immunodiagnostic Systems Holdings plc

Five year distribution agreement

 

Immunodiagnostic Systems Holdings plc ("IDS"), a leading producer of diagnostic testing kits for the clinical and research markets, announces that Technogenetics s.r.l. ("Technogenetics") of Milan, Italy has signed a five year distribution agreement with A. Menarini Diagnostics ("Menarini") covering Europe for an automated test system, the Zenit RA, together with a panel of 21 tests for the diagnosis of autoimmune diseases. The Zenit RA is an OEM version of the IDS-iSYS system.

On 5 October 2009 IDS announced that it had signed an OEM manufacturing and supply agreement with Technogenetics, a subsidiary of Bouty S.p.A, the clinical diagnostics company (see RNS Reach number 1950A). As part of this agreement IDS will supply IDS-iSYS systems and consumables to Technogenetics on an OEM basis. These systems, branded as the Zenit RA, and consumables will be sold by Menarini as 'closed system' instruments throughout the whole of Europe and countries of the former Soviet Union such as Russia and Ukraine. Menarini is a leading company in the diagnostic field, with 14 direct subsidiaries, 1,000 employees and a consolidated turnover of 320 million Euros.

Commenting on the distribution agreement, Lorenzo Castellini, President of the Bouty Group, said: "We expect that over the five years the distribution agreement with A. Menarini Diagnostics will generate approximately €12 million in revenues from sales of diagnostic kits manufactured by Technogenetics with additional income from sales of instruments and ancillary reagents supplied by IDS."

Roger Duggan, CEO of IDS, said: "We're very pleased to see that our collaboration with Technogenetics is about to bear fruit and the deal signed between Technogenetics and Menarini significantly expands the route to market for Technogenetics’ autoimmune products. This can only enhance future sales of IDS-manufactured instruments and ancillary reagents across Europe, a great ‘upside’ to our agreement with Technogenetics.”

 

Enquiries:

 

Immunodiagnostic Systems Holdings Plc

Tel: 0191 519 0660

David Evans, Chairman

 

Roger Duggan, CEO

 

 

 

Brewin Dolphin Investment Banking

Tel: 0845 213 4730

Andrew Emmott

Sean Wyndham-Quin

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8787

Paul McManus

Mob: 07980 541 893

 

paul.mcmanus@walbrookpr.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRKKNDQBBKDODK
Date   Source Headline
27th Oct 20174:23 pmRNSTransaction in Own Shares
23rd Oct 20175:38 pmRNSTransaction in Own Shares
20th Oct 20174:30 pmRNSH1 Trading Update
5th Oct 20179:49 amRNSHolding(s) in Company
5th Oct 20179:42 amRNSHolding(s) in Company
5th Oct 20179:39 amRNSHolding(s) in Company
2nd Oct 20176:08 pmRNSHolding(s) in Company
22nd Sep 20177:25 amRNSTransaction in Own Shares
20th Sep 20176:09 pmRNSTransaction in Own Shares
18th Sep 20173:23 pmRNSTransaction in Own Shares
10th Aug 20172:00 pmRNSLaunch of IDS-iSYS
10th Aug 20178:37 amRNSTransaction in Own Shares
9th Aug 20177:00 amRNSTransaction in Own Shares
2nd Aug 20179:30 amRNSDirector/PDMR Shareholding
2nd Aug 20178:33 amRNSHolding(s) in Company
2nd Aug 20178:30 amRNSHolding(s) in Company
27th Jul 20173:45 pmRNSResult of AGM
27th Jul 20178:00 amRNSTransaction in Own Shares
27th Jul 20177:00 amRNSAGM Statement
24th Jul 20177:00 amRNSTransaction in Own Shares
3rd Jul 20174:12 pmRNSDirector/PDMR Shareholding
28th Jun 20178:28 amRNSDirector/PDMR Shareholding
22nd Jun 20175:33 pmRNSDirector/PDMR Shareholding
21st Jun 20177:30 amRNSPublication of Annual Report and Accounts
21st Jun 20177:01 amRNSShare Buyback Programme
21st Jun 20177:00 amRNSFinal Results
21st Apr 20177:00 amRNSTrading Update
23rd Mar 20179:14 amRNSDirector/PDMR Shareholding
13th Mar 20178:31 amRNSDirectorate Change
1st Mar 201710:01 amRNSLaunch of IDS-iSYS InaKtif MGP assay
24th Feb 20173:31 pmRNSUpdate on CEO Appointment
7th Feb 20172:46 pmRNSHolding(s) in Company
2nd Feb 20173:14 pmRNSLaunch of IDS-iSYS ACTH assay
26th Jan 20173:05 pmRNSHolding(s) in Company
20th Jan 20174:24 pmRNSDirector Dealing
20th Jan 201710:30 amRNSHolding(s) in Company
19th Jan 20171:12 pmRNSDirectorate Change
18th Jan 201712:26 pmRNSHolding(s) in Company
11th Jan 20173:14 pmRNSDirector/PDMR Shareholding
5th Jan 20175:35 pmRNSHolding(s) in Company
5th Jan 20174:38 pmRNSHolding(s) in Company
25th Nov 20168:00 amRNSHalf-year Report
21st Oct 20167:00 amRNSH1 Trading Update
19th Oct 20167:00 amRNSLaunch of IDS-iSYS Total Testosterone assay
28th Jul 20163:18 pmRNSResult of AGM
28th Jul 20167:00 amRNSAGM Statement
11th Jul 201611:46 amRNSDirector/PDMR Shareholding
5th Jul 201610:07 amRNSDirector/PDMR Shareholding
30th Jun 20166:15 pmRNSDirector/PDMR Shareholding
28th Jun 20166:13 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.